The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome
Open accessAbstract
Background: Mast cell activation is thought to be involved in visceral hypersensitivity, one of the main characteristics of the irritable bowel syndrome (IBS). A study was therefore undertaken to investigate the effect of the mast cell stabiliser ketotifen on rectal sensitivity and symptoms in patients with IBS. Methods: 60 patients with IBS underwent a barostat study to assess rectal sensitivity before and after 8 weeks of treatment. After the initial barostat, patients were randomised to receive ketotifen or placebo. IBS symptoms and health-related quality of life were scored. In addition, mast cells were quantified and spontaneous release of tryptase and histamine was determined in rectal biopsies and compared with biopsies from 22 age- and gender-matched healthy volunteers. Results: Ketotifen but not placebo increased the threshold for discomfort in patients with IBS with visceral hypersensitivity. This effect was not observed in normosensitive patients with IBS. Ketotifen significantly decreased abdominal pain and other IBS symptoms and improved quality of life. The number of mast cells in rectal biopsies and spontaneous release of tryptase were lower in patients with IBS than in healthy volunteers. Spontaneous release of histamine was mostly undetectable but was slightly increased in patients with IBS compared with healthy volunteers. Histamine and tryptase release were not altered by ketotifen. Conclusions: This study shows that ketotifen increases the threshold for discomfort in patients with IBS with visceral hypersensitivity, reduces IBS symptoms and improves health-related quality of life. Whether this effect is secondary to the mast cell stabilising properties of ketotifen or H 1 receptor antagonism remains to be further investigated. Trial Registration Number: NTR39, ISRCTN22504486 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barbara, G., Stanghellini, V., De Giorgio, R., Cremon, C., Cottrell, G. S., Santini, D., Pasquinelli, G., Morselli-Labate, A. M., Grady, E. F., Bunnett, N. W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.055 · Cited by 1,475
Svedlund, J., Sj�din, I., & Dotevall, G. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535722 · Cited by 1,468
The physiology of brain histamine
Brown, R. E., Stevens, D. R., & Haas, H. L. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00039-3 · Cited by 988
Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome
Barbara, G., Wang, B., Stanghellini, V., de Giorgio, R., Cremon, C., Di Nardo, G., Trevisani, M., Campi, B., Geppetti, P., Tonini, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.039 · Cited by 783
Role for protease activity in visceral pain in irritable bowel syndrome
Cenac, N., Andrews, C. N., Holzhausen, M., Chapman, K., Cottrell, G., Andrade-Gordon, P., Steinhoff, M., Barbara, G., Beck, P., Bunnett, N. W., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29255 · Cited by 591 · cited 1×
“Fourth, exposure to the supernatant obtained from colonic biopsies of patients with IBS but not from healthy controls increases the excitability of rat mesenteric sensory nerves and induces visceral hypersensitivity in mice.(8) 9 Finally, in animal models, administration of the mast cell stabiliser doxantrazole preven…”
Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum
Guilarte, M., Santos, J., de Torres, I., Alonso, C., Vicario, M., Ramos, L., Martinez, C., Casellas, F., Saperas, E., & Malagelada, J. R. (2007) · Gut · doi:10.1136/gut.2006.100594 · Cited by 385
Buhner, S., Li, Q., Vignali, S., Barbara, G., De Giorgio, R., Stanghellini, V., Cremon, C., Zeller, F., Langer, R., Daniel, H., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.005 · Cited by 351
Self-citationStress‐induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells
GUÉ, M., DEL RIO‐LACHEZE, C., EUTAMENE, H., THÉODOROU, V., FIORAMONTI, J., & BUÉNO, L. (1997) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.1997.d01-63.x · Cited by 282
Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis
Schwartz, L. B., Bradford, T. R., Rouse, C., Irani, A.-M., Rasp, G., Van Der Zwan, J. K., & Van Der Linden, P.-W. G. (1994) · Journal of Clinical Immunology · doi:10.1007/bf01533368 · Cited by 263
Histamine receptors are hot in immunopharmacology
Akdis, C. A., & Simons, F. E. R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.044 · Cited by 260
Cited by
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755
Self-citationRajilić–Stojanović, M., Biagi, E., Heilig, H. G. H. J., Kajander, K., Kekkonen, R. A., Tims, S., & de Vos, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.043 · Cited by 1,041
Vanuytsel, T., van Wanrooy, S., Vanheel, H., Vanormelingen, C., Verschueren, S., Houben, E., Salim Rasoel, S., Tόth, J., Holvoet, L., Farré, R., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305690 · Cited by 615
FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial
McIntosh, K., Reed, D. E., Schneider, T., Dang, F., Keshteli, A. H., De Palma, G., Madsen, K., Bercik, P., & Vanner, S. (2017) · Gut · doi:10.1136/gutjnl-2015-311339 · Cited by 478
Camilleri, M., Lasch, K., & Zhou, W. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00155.2012 · Cited by 396
Metadata
- Authors
- Klooker, T. K., Braak, B., Koopman, K. E., Welting, O., Wouters, M. M., van der Heide, S., Schemann, M., Bischoff, S. C., van den Wijngaard, R. M., & Boeckxstaens, G. E.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2010-07-21
- Volume
- 59
- Issue
- 9
- Pages
- 1213-1221
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2129921159
- Cited by
- 412
- References
- 38
- FWCI
- 31.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. https://app.cochat.ai/papers/10.1136/gut.2010.213108
- The paper
- Klooker, T. K., Braak, B., Koopman, K. E., Welting, O., Wouters, M. M., van der Heide, S., Schemann, M., Bischoff, S. C., van den Wijngaard, R. M., & Boeckxstaens, G. E. (2010). The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. https://doi.org/10.1136/gut.2010.213108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.